Alcohol
Volume 29, Issue 2 , Pages 109-116 , February 2003

μ1-opioid antagonist naloxonazine alters ethanol discrimination and consumption

  • Molina Mhatre

      Affiliations

    • Free Radical Biology and Aging, Oklahoma Medical Research Foundation, 825 N.W. 13th Street, Oklahoma City, OK 73190-3000, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-405-271-8001, ext. 34426, or +1-405-271-7871; fax: +1-405-271-1755
    • ,
  • Frank Holloway

      Affiliations

    • Department of Psychiatry & Behavioral Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190-3000, USA

Received 25 July 2002 ,Revised 31 December 2002 ,Accepted 4 January 2003.

References 

  1. Altshuler HL, Phillips PE, Feinhandler DA. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980;26:679–688
  2. Cruciani RA, Lutz RA, Munson PJ, Rodbard D. Naloxonazine effects on the interaction of enkephalin analogs with mu-1, mu and delta opioid binding sites in rat brain membranes. J Pharmacol Exp Ther. 1987;242:15–20
  3. Files FJ, Samson HH, Brice GT. Sucrose, ethanol, and sucrose/ethanol reinforced responding under variable-interval schedules of reinforcement. Alcohol Clin Exp Res. 1995;19:1271–1278
  4. Froehlich JC, Li T-K. Enkephalinergic involvement in voluntary drinking of alcohol. In:  L. D. Reid LD editors. Opioids, Bullimia, Alcohol Abuse and Alcoholism. New York: Springer-Verlag; 1990;p. 228–271
  5. Froehlich JC, Zweifel M, Harts J, Lumeng L, Li T-K. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl). 1991;103:467–472
  6. Gianoulakis C. The effect of ethanol on the biosynthesis and regulation of opioid peptides. Experientia. 1989;45:428–435
  7. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol Suppl. 1996;1:33–42
  8. Hahn EF, Carroll-Buatti M, Pasternak GW. Irreversibleopiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J Neurosci. 1982;2:572–576
  9. Honkanen A, Vilamo L, Wegelius K, Sarviharju M, Hyytia P, Korpi ER. Alcohol drinking is reduced by a mu-1 but not by a delta-opioid receptor antagonist in alcohol-preferring rats. Eur J Pharmacol. 1996;304:7–13
  10. Hyytia P. Involvement of μ-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol Biochem Behav. 1993;45:697–701
  11. Kiianmaa K, Hoffman PL, Tabakoff B. Antagonism of the behavioral effects of ethanol by naltrexone in BALB/c, C57BL/6, and DBA/2 mice. Psychopharmacology (Berl). 1983;79:291–294
  12. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13:177–184
  13. Kosten TA, Haile CN, Jatlow P. Naltrexone and morphine alter the discrimination and plasma levels of ethanol. Behav Pharmacol. 1999;10:1–13
  14. Krishnan-Sarin S, Portoghese PS, Li T-K, Froehlich JC. The delta2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol Biochem Behav. 1995;52:153–159
  15. Le AD, Poulos CX, Quan B, Chow S. The effects of selective blockade of delta and mu opiate receptors on ethanol consumption by C57BL/6 mice in a restricted access paradigm. Brain Res. 1993;630:330–332
  16. Ling GS, MacLeod JM, Lee S, Lockhart SH, Pasternak GW. Separation of morphine analgesia from physical dependence. Science. 1984;226:462–464
  17. Ling GS, Pasternak GW. Spinal and supraspinal opioid analgesia in the mouse: the role of subpopulations of opioid binding sites. Brain Res. 1983;271:152–156
  18. Ling GS, Simantov R, Clark JA, Pasternak GW. Naloxonazine actions in vivo. Eur J Pharmacol. 1986;129:33–38
  19. Ling GS, Spiegel K, Lockhart SH, Pasternak GW. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther. 1985;232:149–155
  20. Mann PE, Pasternak GW, Hahn EF, Curreri G, Lubin E, Bodnar RJ. Comparison of effects of chronic administration of naloxone and naloxonazine upon food intake and maintenance of body weight in rats. Neuropharmacology. 1988;27:349–355
  21. Matsuzawa S, Suzuki T, Misawa M, Nagase H. Involvement of mu- and delta-opioid receptors in the ethanol-associated place preference in rats exposed to foot shock stress. Brain Res. 1998;803:169–177
  22. Mhatre MC, Patel NP, Holloway FA. Effect of naltrexone and ICS 205-930 on ethanol drinking and feeding behavior. Alcohol Clin Exp Res. 2000;25:14A
  23. O'Malley SS. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol Suppl. 1996;1:77–81
  24. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881–887
  25. Pasternak GW, Childers SR, Snyder SH. Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro. J Pharmacol Exp Ther. 1980;214:455–462
  26. Pasternak GW, Childers SR, Snyder SH. Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors. Science. 1980;208:514–516
  27. Pasternak GW, Wood PJ. Multiple mu opiate receptors. Life Sci. 1986;38:1889–1898
  28. Piepponen TP, Kivastik T, Katajamaki J, Zharkovsky A, Ahtee L. Involvement of opioid mu 1 receptors in morphine-induced conditioned place preference in rats. Pharmacol Biochem Behav. 1997;58:275–279
  29. Pohorecky LA, Brick J. A new method for the determination of blood ethanol levels in rodents. Pharmacol Biochem Behav. 1982;16:693–696
  30. Shippenberg TS, Altshuler HL. A drug discrimination analysis of ethanol-induced behavioral excitation and sedation: the role of endogenous opiate pathways. Alcohol. 1985;2:197–201
  31. Simone DA, Bodnar RJ, Goldman EJ, Pasternak GW. Involvement of opioid receptor subtypes in rat feeding behavior. Life Sci. 1985;36:829–833
  32. Spanagel R. The influence of opioid antagonists on the discriminative stimulus effects of ethanol. Pharmacol Biochem Behav. 1996;54:645–649
  33. Spiegel K, Kourides IA, Pasternak GW. Prolactin and growth hormone release by morphine in the rat: different receptor mechanisms. Science. 1982;217:745–747
  34. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O'Brien CP. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and β-funaltrexamine on ethanol consumption in the rat. Alcohol. 1998;15:281–289
  35. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151:1463–1467
  36. Takemori AE, Portoghese PS. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists. Eur J Pharmacol. 1984;104:101–104
  37. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880
  38. Wolozin BL, Pasternak GW. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc Natl Acad Sci U S A. 1981;78:6181–6185
  39. Zhang AZ, Pasternak GW. Ontogeny of opiate pharmacology and receptors: high and low affinity site differences. Eur J Pharmacol. 1981;73:29–40
  40. Zhang AZ, Pasternak GW. Opiates and enkephalins: a common binding site mediates their analgesic actions in rats. Life Sci. 1981;29:843–851

PII: S0741-8329(03)00021-1

doi: 10.1016/S0741-8329(03)00021-1

Alcohol
Volume 29, Issue 2 , Pages 109-116 , February 2003

Article Tools

* Image Usage & Resolution